Search results for "clinical research"

showing 10 items of 474 documents

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

2019

Regorafenib is one option for second-line treatment of hepatocellular carcinoma (HCC), improving overall survival (OS) of sorafenib-tolerant patients who develop progression. We aim to evaluate the safety and outcomes of regorafenib as second-line treatment for HCC recurrence after liver transplantation (LT). This is a retrospective, multicenter, international study including regorafenib-treated LT patients (2015-2018), with analysis of baseline characteristics and evolutionary events during sorafenib/regorafenib treatment. Twenty-eight LT patients (57 years, 7% cirrhotics, 54% performance status 1) were included. Median time from LT to regorafenib initiation was 3.9 (1.1-18.5) years; media…

MalePyridinesmedicine.medical_treatment030230 surgeryLiver transplantationchemotherapyGastroenterologychemistry.chemical_compound0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyPharmacology (medical)Liver NeoplasmsMiddle AgedSorafenibPrognosisRecurrent Hepatocellular Carcinomaside effectsHepatocellular carcinomaFemalemedicine.drugSorafenibAdultmedicine.medical_specialtyCarcinoma Hepatocellularcancer/malignancy/neoplasiaclinical research/practice03 medical and health sciencesYoung AdultInternal medicineRegorafenibmedicineHumansAdverse effectAgedRetrospective StudiesTransplantationdrug interactionPerformance statusbusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationLiver TransplantationchemistryDrug Resistance NeoplasmNeoplasm Recurrence Localpharmacologybusinessliver transplantation/hepatologyFollow-Up Studies
researchProduct

Adherence to immunomodulatory drugs in patients with multiple myeloma

2018

Background Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. Methods All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomi…

MaleQuestionnairesCancer Treatment030204 cardiovascular system & hematologyPharmacistsPlasma Cell DisordersHematologic Cancers and Related DisordersMathematical and Statistical Techniques0302 clinical medicineSurveys and QuestionnairesMedicine and Health SciencesMedical PersonnelProspective StudiesProspective cohort studyMultiple myelomaMultidisciplinaryQStatisticsRHematologyMyelomasProfessionsOncologyResearch Design030220 oncology & carcinogenesisPhysical SciencesMedicineRegression AnalysisFemaleMultiple MyelomaResearch Articlemedicine.drugmedicine.medical_specialtyDrug AdherenceClinical Research DesignScienceLinear Regression AnalysisResearch and Analysis MethodsMedication Adherence03 medical and health sciencesCronbach's alphaInternal medicinemedicineHumansImmunologic FactorsIn patientMyelomas and Lymphoproliferative DiseasesStatistical MethodsAdverse effectAgedLenalidomidePharmacologySurvey Researchbusiness.industryCancers and NeoplasmsPomalidomidemedicine.diseaseThalidomidePeople and PlacesPopulation GroupingsAdverse EventsbusinessMathematicsPLOS ONE
researchProduct

Disruption of the ASTN2 / TRIM32 locus at 9q33.1 is a risk factor in males for Autism Spectrum Disorders, ADHD and other neurodevelopmental phenotypes

2014

Rare copy number variants (CNVs) disrupting ASTN2 or both ASTN2 and TRIM32 have been reported at 9q33.1 by genome-wide studies in a few individuals with neurodevelopmental disorders (NDDs). The vertebrate-specific astrotactins, ASTN2 and its paralog ASTN1, have key roles in glial-guided neuronal migration during brain development. To determine the prevalence of astrotactin mutations and delineate their associated phenotypic spectrum, we screened ASTN2/TRIM32 and ASTN1 (1q25.2) for exonic CNVs in clinical microarray data from 89 985 individuals across 10 sites, including 64 114 NDD subjects. In this clinical dataset, we identified 46 deletions and 12 duplications affecting ASTN2. Deletions o…

MaleReceptors Cell Surface/geneticsAutismChild Development Disorders Pervasive/geneticsGene ExpressionGenome-wide association studyMedical and Health SciencesTripartite Motif ProteinsRisk FactorsReceptors2.1 Biological and endogenous factorsProtein IsoformsNerve Tissue Proteins/geneticsCopy-number variationAetiologyChildGenetics (clinical)Sequence DeletionPediatricGenetics & HeredityGeneticseducation.field_of_studySingle NucleotideArticlesGeneral MedicineExonsBiological SciencesMental HealthPhenotypeAutism spectrum disorderOrgan SpecificityCerebellar cortexChild PreschoolCell SurfaceSpeech delayFemalemedicine.symptomTranscription Initiation SiteAttention Deficit Disorder with Hyperactivity/geneticsChromosomes Human Pair 9HumanPair 9AdultPediatric Research InitiativeChild Development DisordersAdolescentDNA Copy Number VariationsIntellectual and Developmental Disabilities (IDD)Ubiquitin-Protein LigasesPopulationTranscription Factors/geneticsNerve Tissue ProteinsReceptors Cell SurfaceBiologyPolymorphism Single NucleotideChromosomesYoung AdultClinical ResearchProtein Isoforms/geneticsBehavioral and Social ScienceGeneticsmedicineAttention deficit hyperactivity disorderHumansGenetic Predisposition to DiseasePolymorphismPreschooleducationMolecular BiologyGenetic Association StudiesPervasiveGlycoproteinsHuman GenomeNeurosciencesInfant NewbornGlycoproteins/geneticsInfantNewbornmedicine.diseaseBrain DisordersAttention Deficit Disorder with HyperactivityChild Development Disorders PervasiveCase-Control StudiesAutismTranscription Factors
researchProduct

Deregulation of dicer and mir-155 expression in liposarcoma

2015

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versu…

MaleRibonuclease IIIPathologymedicine.medical_specialtyDEAD-box RNA Helicases -- biosynthesis -- genetics -- metabolismSettore MED/06 - Oncologia MedicaMicroRNAs -- biosynthesis -- geneticsAdipose tissueLiposarcomaRibonuclease III -- biosynthesis -- genetics -- metabolismDroshamiR-155DEAD-box RNA Helicasemir-155DEAD-box RNA HelicasesRetrospective StudiemicroRNAmedicineHumansMicroarray AnalysiDroshaRetrospective StudiesbiologySoft tissue sarcomaAnatomical pathologyMicroRNALiposarcomaSciences bio-médicales et agricolesmedicine.diseaseMicroarray AnalysisLiposarcoma -- genetics -- metabolism -- pathologyDicer; Drosha; liposarcoma; mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease IIIMicroRNAsOncologyliposarcomabiology.proteinlipids (amino acids peptides and proteins)FemaleClinical Research PaperDicerDicer; Drosha; Liposarcoma; Mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease III; OncologyHumanDicer
researchProduct

Differences between Human Plasma and Serum Metabolite Profiles

2011

BackgroundHuman plasma and serum are widely used matrices in clinical and biological studies. However, different collecting procedures and the coagulation cascade influence concentrations of both proteins and metabolites in these matrices. The effects on metabolite concentration profiles have not been fully characterized.Methodology/principal findingsWe analyzed the concentrations of 163 metabolites in plasma and serum samples collected simultaneously from 377 fasting individuals. To ensure data quality, 41 metabolites with low measurement stability were excluded from further analysis. In addition, plasma and corresponding serum samples from 83 individuals were re-measured in the same plate…

MaleSerumClinical Research DesignEpidemiologyScienceMetaboliteProtein metabolismType 2 diabetesPharmacologyBiologyBiochemistryPlasmachemistry.chemical_compoundDiagnostic MedicineBlood plasmaPathologymedicineMetabolomeHumansClinical EpidemiologyBiologyAgedAged 80 and overClinical ChemistryReproducibilityMultidisciplinaryChromatographyQChromatography; Metabolomics; Collection; Samples; Issues; AcidRReproducibility of ResultsMiddle Agedmedicine.diseaseClinical Laboratory SciencesBiomarker EpidemiologychemistrySmall MoleculesBlood ChemistryMetabolomeMedicineBiomarker (medicine)FemaleBiomarkersDrug metabolismResearch ArticleGeneral PathologyPLoS ONE
researchProduct

Exome sequencing in suspected monogenic dyslipidemias.

2015

Background— Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. Methods and Results— We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of commo…

MaleSettore MED/09 - Medicina InternaMedical BiotechnologyDNA sequencing; exome; exome sequencing; genetics human; lipids; mendelian geneticsBiologyCardiorespiratory Medicine and HaematologyNovel genelipidsmendelian geneticsGene mappingClinical ResearchGenetics2.1 Biological and endogenous factorsHumansgeneticsExomeDNA sequencinghumanAetiologyMendelian disordersExomeGenetics (clinical)Exome sequencingDyslipidemiasGeneticsInborn ErrorsHuman GenomeHigh-Throughput Nucleotide SequencingAtherosclerosisMetabolismCardiovascular System & Hematologylipids (amino acids peptides and proteins)DNA sequencing; exome; genetics; human; lipidsFemalegeneticCardiology and Cardiovascular Medicineexome sequencingexomeMetabolism Inborn ErrorsCirculation. Cardiovascular genetics
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis.

2011

Background Therapy of atopic dermatitis (AD) relies on immunosuppression and/or UV irradiation. Here, we assessed clinical efficacy and histopathological alterations induced by blue light-treatment of AD within an observational, non-interventional study. Methodology/Principal Findings 36 patients with severe, chronic AD resisting long term disease control with local corticosteroids were included. Treatment consisted of one cycle of 5 consecutive blue light-irradiations (28.9 J/cm2). Patients were instructed to ask for treatment upon disease exacerbation despite interval therapy with topical corticosteroids. The majority of patients noted first improvements after 2–3 cycles. The EASI score w…

MaleSkin PhysiologyAnatomy and PhysiologyLightmedicine.medical_treatmentlcsh:MedicinePediatric DermatologyAntigen Processing and RecognitionAtopic DermatitisDiseasePediatricsQuality of lifeYoung adultlcsh:ScienceSkinMultidisciplinarymedicine.diagnostic_testT CellsAllergy and HypersensitivityPhysicsElectromagnetic RadiationPhotodermatology and Skin AgingImmunosuppressionAtopic dermatitisMiddle Agedmedicine.anatomical_structureTreatment OutcomePatient SatisfactionObservational StudiesMedicineFemaleWhole-Body IrradiationResearch ArticleAdultmedicine.medical_specialtyLangerhans cellClinical Research DesignImmune CellsImmunologyColorDermatologyDermatitis AtopicYoung AdultUltraviolet RadiationBiopsymedicineHumansSerologic TestsBiologybusiness.industrylcsh:Rmedicine.diseaseDermatologyClinical trialImmune SystemChronic DiseaseQuality of Lifelcsh:QClinical ImmunologybusinessPloS one
researchProduct

Learning to Eat Vegetables in Early Life: The Role of Timing, Age and Individual Eating Traits

2014

Vegetable intake is generally low among children, who appear to be especially fussy during the pre-school years. Repeated exposure is known to enhance intake of a novel vegetable in early life but individual differences in response to familiarisation have emerged from recent studies. In order to understand the factors which predict different responses to repeated exposure, data from the same experiment conducted in three groups of children from three countries (n = 332) aged 4-38 m (18.9 +/- 9.9 m) were combined and modelled. During the intervention period each child was given between 5 and 10 exposures to a novel vegetable (artichoke puree) in one of three versions (basic, sweet or added e…

MaleTasteTime Factorsplate-clearerPhysiologyEpidemiology030309 nutrition & dieteticshabitude alimentaireNovel foodPediatrics0302 clinical medicineFeeding behaviorVegetablesMedicine and Health SciencesPsychologyMedicinePublic and Occupational HealthFood sciencetoddlersPediatric EpidemiologyEating behaviourenfant2. Zero hunger0303 health scienceslearningMultidisciplinaryinfantsQAge FactorsChild HealthRExperimental Psychologyacceptation de légumeapprentissageEarly lifePhysiological ParametersResearch DesignChild PreschoolAlimentation et NutritionMedicineFemaleBehavioral and Social Aspects of HealthResearch ArticleallaitementClinical Research DesignScienceconsommation alimentaire030209 endocrinology & metabolismResearch and Analysis MethodsfussinessFood Preferences03 medical and health scienceschildrenIntervention (counseling)vegetable intakecaractère alimentaire difficileFood and NutritionHumansObesityNutritionBehaviorbusiness.industryBody WeightCognitive PsychologyInfantBiology and Life ScienceslégumeFeeding Behaviorjeune enfantchildren;toddlers;infants;vegetable intake;learning;fussiness;age;eating traits;plate-clearer;non-eater;jeune enfant;nourrisson;acceptation de légume;apprentissage;caractère alimentaire difficilenon-eaternourrissonageExposure periodCognitive Scienceeating traitsbusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBreast feedingNeuroscienceDemographyPLoS ONE
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct